KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Deferred Taxes (2020 - 2025)

Pacira BioSciences (PCRX) has 6 years of Deferred Taxes data on record, last reported at -$3.7 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 206.73% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached $6.5 million, down 68.59%, while the annual FY2025 figure was $6.5 million, 68.59% down from the prior year.
  • Deferred Taxes reached -$3.7 million in Q4 2025 per PCRX's latest filing, down from $8.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $12.5 million in Q2 2024 and bottomed at -$10.8 million in Q4 2022.
  • Average Deferred Taxes over 5 years is $2.3 million, with a median of $2.0 million recorded in 2021.
  • Peak YoY movement for Deferred Taxes: plummeted 25417.24% in 2023, then surged 623.95% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at -$2.1 million in 2021, then tumbled by 420.9% to -$10.8 million in 2022, then skyrocketed by 160.89% to $6.6 million in 2023, then plummeted by 46.86% to $3.5 million in 2024, then plummeted by 206.73% to -$3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$3.7 million in Q4 2025, $8.1 million in Q3 2025, and $752000.0 in Q2 2025.